Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, given alone and combined with cetuximab, in patients with metastatic non-small cell lung cancer NSCLC that have a specific KRAS G12D mutation. This phase 2 open-label study focuses on patients who have already received prior treatments and whose cancer has progressed. The goal is to better understand how this oral KRAS G12D inhibitor works in this advanced lung cancer setting. Participants will receive VS-7375 orally in one of several dosing regimens depending on their prior treatments and disease characteristics, including groups for second or third line 2L3L therapy and those with brain metastases receiving second to fourth line 2L-4L therapy. The study uses a randomized crossover design and will assess responses to treatment over time. Different doses may be provided, and participants may be monitored for disease progression and side effects during the treatment period. Throughout the trial, participants will have regular evaluations including imaging scans to measure tumor size according to RECIST criteria, safety assessments, blood tests for pharmacokinetics and pharmacodynamics, and quality of life questionnaires. The main outcomes include confirmed tumor response rates and safety over six months, with additional measures tracked up to 2.5 years. The study will also observe time to next therapy and health-related quality of life changes, with monitoring continuing through the planned study period until 2028.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of VS-7375, an oral KRAS G12D ONOFF inhibitor, alone and combined with cetuximab in patients with metastatic pancreatic ductal adenocarcinoma PDAC that has the KRAS G12D mutation. This Phase 2, open-label study aims to understand how these treatments work in this specific patient group. The trial is sponsored by Verastem, Inc. and uses a randomized, parallel design.
Actively Recruiting
Researchers are evaluating whether adding zilovertamab vedotin to the standard treatment can help people with previously untreated diffuse large B-cell lymphoma DLBCL live longer without their cancer growing or spreading. This phase 3 randomized study compares the combination of zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin, and prednisone R-CHP against the standard treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP. Participants receive treatments in 21-day cycles for up to six cycles approximately four months. One group receives zilovertamab vedotin with rituximab or its biosimilar, cyclophosphamide, doxorubicin, and prednisone or similar steroids, while the other group receives rituximab or its biosimilar, cyclophosphamide, doxorubicin, vincristine, and prednisone or similar steroids. Both groups may receive up to two additional cycles of rituximab or its biosimilar as decided by the investigator. During the study, participants will have regular assessments including imaging scans and heart function tests to monitor their health and response to treatment. Researchers will measure how long participants live without disease progression, overall survival, response rates, and quality of life up to several years. Safety is monitored by tracking adverse events and treatment discontinuations. The study lasts several years, with primary outcome assessments up to about 50 months and overall survival monitored up to approximately 74 months.
Actively Recruiting
Researchers are evaluating INCB123667 compared to the investigators choice of chemotherapy in women with platinum-resistant ovarian cancer that shows cyclin E1 overexpression. This phase 3, randomized, open-label study aims to assess treatment options for this specific type of ovarian cancer, focusing on progression-free survival and overall survival over up to 2 years. Participants will receive either oral INCB123667 tablets at a dose defined by the study protocol or chemotherapy selected by the investigator according to protocol guidelines. The chemotherapy options are also given at protocol-defined doses. The study compares these two treatment approaches administered in parallel groups. During the trial, participants will be monitored for treatment responses and side effects, with evaluations including tumor measurements according to RECIST criteria and quality of life questionnaires at regular visits for up to 2 years. Safety assessments include tracking adverse events and dose modifications. The study will involve regular visits to assess progression-free survival, overall survival, and other clinical outcomes.